<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02456038</url>
  </required_header>
  <id_info>
    <org_study_id>HPPJEAP-01</org_study_id>
    <secondary_id>UMIN000014816</secondary_id>
    <nct_id>NCT02456038</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Asfotase Alfa in Patients With Hypophosphatasia (HPP)</brief_title>
  <official_title>A Multicenter Study of the Safety and Efficacy of Asfotase Alfa (ALXN1215) (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in Patients With Hypophosphatasia (HPP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Osaka University Graduate School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess safety and efficacy of Asfotase Alfa (ALXN1215) in
      patients with hypophosphatasia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with Adverse Events as an assessment of the Safety of repeated subcutaneous (SC) injections of asfotase alfa</measure>
    <time_frame>Up to 50 months or until regulatory approval</time_frame>
    <description>Safety of repeated subcutaneous (SC) injections of asfotase alfa for all treated patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 50 months or until regulatory approval</time_frame>
    <description>Overall survival is defined as the time from birth to time of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of asfotase alfa treatment on skeletal manifestations of HPP as measured by radiographs using a qualitative Radiographic Global Impression of Change (RGI-C) scale</measure>
    <time_frame>Up to 50 months or until regulatory approval</time_frame>
    <description>Effect of asfotase alfa treatment on skeletal manifestations of HPP as measured by radiographs using a qualitative Radiographic Global Impression of Change (RGI-C) scale for all treated patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of asfotase alfa treatment on ventilator-free survival: (percentage of patients who are alive and ventilator-free after receiving asfotase alfa)</measure>
    <time_frame>Up to 50 months or until regulatory approval</time_frame>
    <description>For patients who are not mechanically ventilated at the time of enrollment, the percentage who are alive and ventilator-free after receiving asfotase alfa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of asfotase alfa treatment on respiratory function</measure>
    <time_frame>Up to 50 months or until regulatory approval</time_frame>
    <description>Effect of asfotase alfa treatment on respiratory function as measured by ventilator status, time on respiratory support (including time on ventilator or supplemental oxygen), ventilator rate or oxygen volume, ventilator pressures, and fraction of inspired oxygen (FiO2) for all treated patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of asfotase alfa treatment on physical growth</measure>
    <time_frame>Up to 50 months or until regulatory approval</time_frame>
    <description>Effect of asfotase alfa treatment on physical growth as measured by body weight, length, arm span, head circumference, and chest circumference for all treated patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of asfotase alfa treatment on development</measure>
    <time_frame>Up to 50 months or until regulatory approval</time_frame>
    <description>Assessment of changes in gross motor development as measured by the developmental motor milestones for all treated patients</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Hypophosphatasia</condition>
  <arm_group>
    <arm_group_label>Asfotase Alfa (ALXN1215)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asfotase Alfa (ALXN1215) is administered 6mg/kg in total per week, divided into 3 times.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asfotase Alfa (ALXN1215)</intervention_name>
    <arm_group_label>Asfotase Alfa (ALXN1215)</arm_group_label>
    <other_name>ALXN1215</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients must meet one selection criteria of following &quot;1&quot;, &quot;2&quot;, and &quot;3&quot;, and must meet the
        selection criteria of &quot;4.&quot;

          1. Patient who has been already treated with Asfotae Alfa (ALXN1215) out of this clinical
             trial

          2. Patient who has been diagnosed as HPP

          3. Documented diagnosis of HPP as indicated by:

          1. Total serum alkaline phosphatase below the lower limit of normal for age

          2. Ultrasonographic features of prenatal, characterized by:

        1) severe short extremities (femur length &lt;-4SD in second and third trimesters) 2)
        extending into the metaphysis (femur metaphysis length or femur length &gt;0.33) 3)
        craniotabes 4) Hypoplastic thorax (Thoracic or abdominal circumference &lt;0.6) (3) Computed
        tomographic findings of prenatal, characterized by:

          1. Generalized decreased ossification

          2. Extreme shortening of tubular bones

          3. Hypoplastic thorax (4) Radiographic evidence of HPP, characterized by:

        1) Flared and frayed metaphyses 2) Severe, generalized osteopenia 3) Widened growth plates
        4) Areas of radiolucency or sclerosis (5) Two or more of the following HPP-related
        findings:

          1. History or presence of:

             - Nontraumatic post-natal fracture

             - Delayed fracture healing

          2. Nephrocalcinosis or history of elevated serum calcium

          3. Functional craniosynostosis

          4. Respiratory compromise or rachitic chest deformity

          5. Vitamin B6 dependent seizures

          6. Failure to thrive

          7. Premature tooth loss (6) Patient who have the mutation of tissue non-specific ALP gene
             4. Parent or legal guardian(s) must provide written informed consent prior to any
             study procedures being performed and must be willing to comply with all study-required
             procedures

        Exclusion Criteria:

          1. Current evidence of treatable form of rickets

          2. Serum calcium or phosphate levels below the normal range

          3. Pregnant women and nursing mothers

          4. Patient who cannot enforce suitable contraceptive measures during the clinical trial

          5. Prior treatment with bisphosphonates

          6. Treatment with an investigational drug within 1 month prior to the start of asfotase
             alfa treatment

          7. Current enrollment in any other study involving an investigational new drug, device or
             treatment for HPP (e.g., bone marrow transplantation)

          8. Clinically significant disease that precludes study participation, in the opinion of
             the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keiichi Ozono</last_name>
    <role>Principal Investigator</role>
    <affiliation>Osaka University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Kurume-city</city>
        <state>Fukuoka-prefecture</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Nagara Medical Center</name>
      <address>
        <city>Gifu-city</city>
        <state>Gifu-prefecture</state>
        <zip>502-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima-city</city>
        <state>Hiroshima-prefecture</state>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo-city</city>
        <state>Hokkaido-prefecture</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai-city</city>
        <state>Miyagi-prefecture</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata University Medical &amp; Dental Hospital</name>
      <address>
        <city>Niigata-city</city>
        <state>Niigata-prefecture</state>
        <zip>951-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Medical Center and Research Institute for Maternal and Child Health</name>
      <address>
        <city>Izumi-city</city>
        <state>Osaka-prefecture</state>
        <zip>594-1101</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita-city</city>
        <state>Osaka-prefecture</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Children's Medical Center</name>
      <address>
        <city>Saitama-city</city>
        <state>Saitama-prefecture</state>
        <zip>339-0077</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamamatsu University Hospital</name>
      <address>
        <city>Hamamatsu-city</city>
        <state>Shizuoka-prefecture</state>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nippon Medical School Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8603</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Showa General Hospital</name>
      <address>
        <city>Kodaira-city</city>
        <state>Tokyo</state>
        <zip>187-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2015</study_first_submitted>
  <study_first_submitted_qc>May 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2015</study_first_posted>
  <last_update_submitted>March 29, 2016</last_update_submitted>
  <last_update_submitted_qc>March 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypophosphatasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

